Dark Blue Therapeutics

News

Amgen has added a new acute myeloid leukaemia drug with the takeover of Dark Blue Therapeutics and its first-in-class MLLT 1/3 degrader.

News

A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.